Screener / SEC EDGAR /CIK 0001604821 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Medical Labs

Natera, Inc. NTRA

Note: A glossary of terms used in this Form 10-K appears at the end of this Item 1. 10-K, Item 1

Headquarters
Austin, TX
CEO
Steven Leonard Chapman
Next results
around Jan 11, 2027
Compare with peers Embed

NTRA among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 35.9%, above 85% of 154 peers (their median 10.4%) REVENUE GROWTH 35.9% · above 85% Operating margin: -9.0%, above 20% of 138 peers (their median 10.2%) OPERATING MARGIN -9.0% · above 20% Net margin: -5.7%, above 23% of 153 peers (their median 6.8%) NET MARGIN -5.7% · above 23% FCF margin: 1.8%, above 22% of 144 peers (their median 10.1%) FCF MARGIN 1.8% · above 22%
NTRA Peer median Below the median

What changed

8 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 27, 2026 against Feb 28, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Inventory growing faster than revenue
    Inventory +53.0% ($44.7M to $68.4M) vs revenue +35.9% ($1.7B to $2.3B), +17.1 pts apart
  • Critical audit matters changed
    New this year: Valuation of Developed Technology Intangible Asset Acquired in a Business Combination (“As described in Note 3 to the consolidated financial statements, on December 4, 2025, the Company completed its acquisition of Foresight Diagnostics, Inc. (“Foresight Diagnostics”). The transaction was accounted for as a business combination using the acquisition method of accounting. The acquisitio”). Same as last year: Product Revenue
  • Receivables -5.6% ($314.2M to $296.5M) vs revenue +35.9% ($1.7B to $2.3B), -41.5 pts apart
8 more checks with nothing to note
  • Cash from operations $215.3M vs net income −$208.2M (FY ending Dec 31, 2025)
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

8 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.

All 8 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    We are incorporating artificial intelligence across various areas of our business, which presents risks that could adversely affect our business and results of operations. We are incorporating artificial intelligence, or AI, and machine learning, or ML, technologies into aspects of our business. The development and use of these…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    We may not be able to obtain approval from the FDA for Signatera PMAs currently under review or for applications that we may submit to FDA in the future. We have submitted PMAs for Signatera for approval as a companion diagnostic. We may face difficulties in obtaining approval of these PMAs for a variety of reasons, including failure to…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    Moreover, our clinical trials to support PMA approval must be conducted under an FDA-approved IDE. FDA has the authority to deny IDE submissions, or to suspend or revoke IDEs once granted, under certain conditions, including noncompliance with FDA requirements or undue risks to subjects. If we are unable to maintain our current IDEs or…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$820.2M$1.1B$1.7B$2.3B
Net income−$547.8M−$434.8M−$190.4M−$208.2M
Operating cash flow−$431.5M−$247.0M$135.7M$215.3M
Free cash flow−$479.2M−$286.2M$69.2M$109.1M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$2.3B ▲ 35.9% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

32 filings in the last 30 days · SEC EDGAR

All filings
27 more

About the company

Natera, Inc., Austin, TX · from the 10-K filed Feb 27, 2026

Note: A glossary of terms used in this Form 10-K appears at the end of this Item 1. We are a diagnostics company with proprietary molecular and bioinformatics technology that we are applying to change disease management worldwide. Our cell-free DNA, or cfDNA, technology combines our novel molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell, with our statistical algorithms that incorporate data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with high accuracy and coverage.

Headquarters
Austin, TX
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NTRA/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.